Novel agents for the prevention of leishmaniasis
OwnerJean-Loup Lemesre, Mireille Cavaleyra +2inventors
InventorsJEAN-LOUP LEMESRE, MIREILLE CAVALEYRA, DENIS SERENO, PHILIPPE HOLZMULLER
Life of this patent
Estimating the term…
Loading patent…
OwnerJean-Loup Lemesre, Mireille Cavaleyra +2inventors
InventorsJEAN-LOUP LEMESRE, MIREILLE CAVALEYRA, DENIS SERENO, PHILIPPE HOLZMULLER
Estimating the term…
The invention relates to nucleic acid constructions, characterized in that they comprise nucleic acids which are isolated in the sense position and which are capable of coding for an immunogenic protein of promastigotes or amastigotes of Leishmania, said nucleic acids responding to one of the sequences SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5 et SEQ ID NO:11 and coding for a protein respectively exhibiting a sequence SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10 et SEQ ID NO:12. The invention can be used for over-expression of the genes of Leishmania coding for an excretion/secretion antigen.
An isolated immunogenic glycoprotein comprising SEQ ID NO:7, said glycoprotein being a Leishmaniasis surface antigen and an excreted/secreted antigen with an apparent molecular weight of 42.5 kDa.
An isolated immunogenic glycoprotein, the protein being encoded by a nucleic acid sequence comprising SEQ ID NO:2, said glycoprotein being a Leishmaniasis surface antigen and an excreted/secreted antigen with an apparent molecular weight of 42.5 kDa.
An isolated peptide encoded by a nucleic acid sequence comprising SEQ ID NO:2 or comprising SEQ ID NO:7.
Dependencies are inferred from the claim text.